NIH backs AlphaRose's AI-designed therapy for ultra-rare Bain syndrome
What's the deal? AlphaRose TherapeuticsDealroom has a profile for this one. Try Dealroom → has won a Small Business Innovation Research (SBIR) Fast Track grant from the National Institutes of HealthDealroom has a profile for this one. Try Dealroom → to advance Rosiphersen (ART-001), its lead antisense oligonucleotide therapy for Bain syndrome. The Austin-based startup designed the candidate using its own AI drug design platform, RINAE.AIDealroom has a profile for this one. Try Dealroom →.
Why it matters: Bain syndrome is an ultra-rare pediatric neurodevelopmental disease caused by variants in the HNRNPH2 gene. It causes severe developmental delay, autism, seizures, and impaired motor function, and has no cure. Roughly 185 cases have been confirmed to date.
What's the endgame? The grant will push Rosiphersen toward an Investigational New Drug application. AlphaRose is targeting first-in-human safety data by the end of 2027, alongside IND-enabling studies and a natural history study.
The founder's story: Chief executive officer and founder Casey McPherson started the company after his daughter, Rose, was diagnosed with an ultra-rare genetic disease with no cure. He called the grant "a pivotal milestone for AlphaRose and the patients we serve."
Why now? AlphaRose says RINAE.AI cuts drug discovery timelines "from months to minutes," using machine learning and predictive algorithms to design oligonucleotide candidates. Chief scientific officer Robert M. Cabrera said the milestone "underscores the power of the RINAE.AI platform to create a repeatable, scalable model for genetic medicine."
The signal: Rosiphersen is being positioned as proof of principle for AlphaRose's platform, which it wants to turn into a repeatable engine for rare disease drug development. Non-dilutive government funding gives the startup runway to reach the clinic without raising equity — and a chance to show that AI-generated therapies can survive regulatory scrutiny.
Read more: biotechnewswire.ai
Image credit: Centers for Disease Control and Prevention
